AZD 0186
Alternative Names: AZD-0186Latest Information Update: 07 Nov 2023
At a glance
- Originator AstraZeneca
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Pharmacokinetics data from a preclinical studies for type 2 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 31 Jul 2023 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in USA (PO) before July 2023 (AstraZeneca Pipeline, July 2023)
- 10 May 2023 AstraZeneca terminates a phase I trial in type 2 diabetes mellitus (In volunteers) in USA (PO) due to the overall data profile obtained from this study which did not demonstrate sufficient differentiation to surpass the current standard of care (NCT05694741)